| Name | Title | Contact Details |
|---|
Welcome to Redpin Therapeutics. We are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.
Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.
The IMV Technologies Group is a leader in the areas of animal and human assisted reproduction technologies and veterinary imaging. IMV Technologies provides customers with solutions for animal artificial insemination; its human division, Cryo Bio System, offers solutions for human assisted reproduction including human embryo vitrification, human sperm freezing and preservation and other assisted reproduction technologies. The IMV imaging business provides customers with veterinary imaging solutions.
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in clinical and commercial manufacturing production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.